Hawaii Biotech, Inc.
Company facts
- Self-certified in SAM.gov
- Entity structure
- Corporate Entity (Not Tax Exempt)
- Other NAICS codes in SAM.gov
- SAM.gov registration date
- Website
- hibiotech.com
- Founded
- 1982
- Employees
- 11-50
- Estimated annual revenue
- $1M-$10M
- Industry
-
- Health Care
- Pharmaceuticals, Biotechnology & Life Sciences
- Pharmaceuticals
- SIC code
- 28 Chemical & Allied Products
- Profiles
Registration and certifications come from SAM.gov and the SBA; company details from public web sources. Updated .
Contract obligations by fiscal year
| Fiscal year | Obligated |
|---|---|
| FY2027 To date | $0 |
| FY2026 | -$1,636 |
| FY2025 | -$1,384,268 |
| FY2024 | -$21,379 |
| FY2023 | $1,931,989 |
Contract awards
Latest 5 listed here. See the rest on GovTribe.
Grant awards
Latest 5 listed here. See the rest on GovTribe.
Similar vendors
About the company
Hawaii Biotech, Inc. (HBI) is a biotechnology company focused on the research and development of prophylactic vaccines for infectious diseases. They are developing small molecule drug candidates for the treatment of Anthrax intoxication and botulism.
Through federal contracts, HBI has provided vaccine development services to the Department of Health and Human Services (HHS) National Institutes of Health (NIH) National Institute of Allergy and Infectious Diseases (NIAID). In 2022, HBI was awarded a $2,997,218 firm fixed price contract under a total small business set aside to provide a Recombinant West Nile Virus Vaccine Adjuvanted with SLA-LSQ to NIAID. The contract runs through 2025 with performance taking place in Honolulu, Hawaii.
HBI has also received several federal grant awards from NIAID to fund vaccine research and development efforts. In 2023, they received a $611,830 Project Grant under CFDA 93.855 (Allergy and Infectious Diseases Research) to identify TLR-4 agonists with immunostimulatory properties suitable for development as vaccine adjuvants over a 2-year period. Activities include establishing synthesis routes, screening compounds, and evaluating immunogenic potency and safety compared to existing West Nile virus vaccines. Another 2023 NIAID Project Grant for $816,117 supports the development of a cross-protective New World Encephalitic Alphavirus subunit vaccine targeting Eastern, Venezuelan and Western Equine Encephalitis viruses in collaboration with Baylor College of Medicine over 2 years.
Quick answers
Is Hawaii Biotech, Inc. registered in SAM.gov?
Hawaii Biotech, Inc.'s SAM.gov registration expired on July 2, 2026.
What is Hawaii Biotech, Inc.'s CAGE code?
Hawaii Biotech, Inc.'s CAGE code is 0EAY9, and its Unique Entity ID (UEI) is ECJKEEFL4L51.
How much has Hawaii Biotech, Inc. received in federal contracts?
Federal contracts obligated $524,706 to Hawaii Biotech, Inc. in fiscal years 2023 through 2027.
What is Hawaii Biotech, Inc.'s most recent federal award?
Hawaii Biotech, Inc.'s most recent federal grant award is Novel TLR-4 agonists as vaccine adjuvants (R43AI174478), from National Institute of Allergy and Infectious Diseases (NIH), on May 2, 2023.
On GovTribe
See Hawaii Biotech, Inc.'s full federal record
- Federal contract awards
- IDV awards
- Federal grant awards
- Subcontracting relationships
- Funding analysis by agency, NAICS and set-aside
- Similar vendors